MabVax Therapeutics Holdings Inc. (fka MBVXQ)

[BiotechValues]

Nice hints in August 11 10-Q filing that upcoming pr on Phase I trial will be positive

"Of the nine patients who have been dosed to date, five have been treated for three or more months and investigator observations have noted stable disease for a subset of those patients. We are continuing to escalate the drug dose to assess safety and reach an MTD and anticipate initiating the second portion of the trial where our drug is dosed in combination with chemotherapy in the fourth quarter of this year. We expect to have the preliminary results of this clinical trial later in the third quarter in 2016.”

Stable disease in a subset of patients- pancreatic cancer and "stable disease" are not usually found in the same sentence.